Who Paid My Doc
Lev Lubarsky
Cardiovascular Disease East Setauket, NY Doctor of Osteopathy
NPI 1093878399 CMS profile 231370
45 Research Way, Suite 008 & 108, East Setauket, NY 11733
General payments
$2,120
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Lev Lubarsky of East Setauket, NY is reported in the CMS Open Payments database as having received $2,120 across 17 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 51st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,509 | 4 | |
| 2024 | General | $274 | 2 | |
| 2022 | General | $17 | 1 | |
| 2020 | General | $124 | 1 | |
| 2019 | General | $195 | 9 |
Beside peers
- Lev Lubarsky
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Lev Lubarsky were reported at $1,509. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Lev Lubarsky | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $195 | $450 | $127–$1,392 | $163 |
| 2020 | $124 | $242 | $77–$751 | $114 |
| 2021 | $0 | $335 | $101–$1,037 | $132 |
| 2022 | $17 | $395 | $121–$1,211 | $149 |
| 2023 | $0 | $443 | $136–$1,283 | $160 |
| 2024 | $274 | $450 | $136–$1,323 | $164 |
| 2025 | $1,509 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 50 drugsPart D claims
3,696
Drug cost
$523,855
Branded share of claims
20.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 169 | $267,834 | |
| Xarelto Rivaroxaban | Brand | 49 | $64,931 | |
| Entresto Sacubitril/Valsartan | Brand | 35 | $55,849 | |
| Multaq Dronedarone Hcl | Brand | 15 | $33,187 | |
| Repatha Sureclick Evolocumab | Brand | 31 | $21,632 | |
| Metoprolol Succinate | Generic | 476 | $10,447 | |
| Farxiga Dapagliflozin Propanediol | Brand | 12 | $9,377 | |
| Praluent Pen Alirocumab | Brand | 12 | $8,944 | |
| Rosuvastatin Calcium | Generic | 404 | $6,080 | |
| Candesartan Cilexetil | Generic | 56 | $5,201 |
The 10 drugs with the highest cost, of 50 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 52 billing codesPaid by Medicare
$1,025,351
Medicare patients
1,979
Services billed
15,356
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 63% | |
| Arthritis | 51% | |
| Diabetes | 36% | |
| Atrial fibrillation | 34% | |
| Chronic kidney disease | 29% | |
| Heart failure | 26% | |
| Cancer | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, regadenoson, 0.1 mg J2785 | Office | 279 | 1,116 | $6,491 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 60 | 6,110 | $641 |
| Injection, aminophyllin, up to 250 mg J0280 | Office | 94 | 94 | $608 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
17 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in New York
Roger Hajjar
Cardiovascular Disease · New York, NY
Szilard Voros
Cardiovascular Disease · Stony Brook, NY
Gregg Stone
Cardiovascular Disease · New York, NY
Augustin Delago
Cardiovascular Disease · Albany, NY
Philippe Genereux
Cardiovascular Disease · New York, NY
Adam Rosenbluth
Cardiovascular Disease · New York, NY
Related records
Cardiovascular Disease in New York
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.